Last edition
News about "ulcerative colitis "
Lilly's Omvoh Shows Early, Sustained Relief in Bowel Urgency for Ulcerative Colitis
Lilly’s Phase 3b LUCENT-URGE results show that Omvoh (mirikizumab-mrkz) provides early and sustained improvements in bowel urgency in ulcerative colitis. The study is the first in inflammatory bowel disease to assess urgency across severity, frequency, and stool deferral time.
Ulcerative Colitis | 28/10/2025 | By Dineshwori
MSN Laboratories Launches Affordable JAK Inhibitors to Boost Access for Indian Patients
The launch of JAK inhibitors enhances the accessibility and affordability of advanced treatments for patients suffering from various autoimmune diseases, including Rheumatoid Arthritis, Psoriatic Arthritis, Ulcerative Colitis, Crohn's Disease and Atopic Dermatitis. Both molecules are also approved by the US FDA.
Ulcerative Colitis | 14/10/2025 | By Dineshwori
Merck Expands Tulisokibart Phase-2(b) Trials Across Three Inflammatory Diseases
Tulisokibart is an investigational anti-TL1A monoclonal antibody currently in Phase-3 trials for Ulcerative Colitis and Crohn’s disease, to be studied in hidradenitis suppurativa, radiographic axial spondyloarthritis and Rheumatoid Arthritis.
Ulcerative Colitis | 07/10/2025 | By Dineshwori | 160
Onco3R Therapeutics Advances Phase 1 Trial of Novel SIK3 Inhibitor Targeting Autoimmune Diseases
Pierre Raboisson, CEO and Founder of Onco3R Therapeutics, said that the final results of the Phase 1 trial of O3R-5671 are expected in the first half of 2026.
Ulcerative Colitis | 06/10/2025 | By Dineshwori
Prometheus Laboratories Collaborates with Celltrion for Anser Testing
Prometheus is the first specialty lab to validate TDM testing for both intravenous and subcutaneous infliximab, supporting the growing demand for at-home treatment options.
Ulcerative Colitis | 28/08/2025 | By Dineshwori
Polpharma Biologics, Fresenius Kabi Partners to Commercialise A Proposed Vedolizumab Biosimilar
Polpharma Biologics, a European biotechnology company, has entered into a global licensing agreement with German multinational healthcare firm Fresenius Kabi for the commercialisation of PB016—a proposed biosimilar to vedolizumab.
Ulcerative Colitis | 06/08/2025 | By Dineshwori | 164
Johnson & Johnson Gets US FDA Approval for TREMFYA
TREMFYA is the first and only approved fully human, dual-acting monoclonal antibody that blocks IL-23 while also binding to CD64, a receptor on cells that produce IL-23.
Ulcerative Colitis | 12/09/2024 | By Aishwarya | 377
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy